Cowen analyst Joshua Jennings raised the firm’s price target on DexCom to $125 from $114 and keeps an Outperform rating on the shares. The analyst remains bullish about G7’s global rollout as the US launch is now underway. DexCom also has another substantial opportunity with CMS’s planned coverage of CGM for basal insulin users which should begin by midyear.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
